Compare SHEN & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | MRVI |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.5M | 449.6M |
| IPO Year | N/A | 2020 |
| Metric | SHEN | MRVI |
|---|---|---|
| Price | $10.87 | $3.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $26.00 | $4.54 |
| AVG Volume (30 Days) | 300.6K | ★ 1.3M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $351,674,000.00 | $192,435,000.00 |
| Revenue This Year | $10.77 | N/A |
| Revenue Next Year | $6.16 | $7.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $9.67 | $1.67 |
| 52 Week High | $15.84 | $6.21 |
| Indicator | SHEN | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 58.83 |
| Support Level | $10.65 | $3.32 |
| Resistance Level | $10.96 | $3.76 |
| Average True Range (ATR) | 0.34 | 0.23 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 74.92 | 80.00 |
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.